GlassScriptPhysician profile
Rajiv Bhambri
NPI 1376537373
$5,359.15
in general payments reported to CMS, 2019-2025
39 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,886 · 2020: $383 · 2021: $1,126 · 2022: $733 · 2023: $474 · 2024: $350 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,230.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.73 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $546.75 | 2019-2023 | Mounjaro |
| Medtronic, INC. | $351.31 | 2021-2024 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $300.36 | 2019-2021 | |
| Abbott Laboratories | $292.21 | 2019-2023 | Freestyle Libre 3 |
| Amgen INC. | $277.05 | 2019-2025 | Tepezza, Prolia, Evenity |
| Tandem Diabetes Care, INC. | $270.52 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $256.86 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $231.50 | 2019-2023 | |
| Dexcom, INC. | $221.44 | 2019-2023 | Dexcom G6 Transmitter |
| Mannkind Corporation | $189.93 | 2019-2023 | Afrezza |
| Medtronic Minimed, INC. | $178.08 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $174.28 | 2024-2025 | Strensiq |
| Amarin Pharma, INC. | $157.03 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.11 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Bhambri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.